INmune Bio (INMB) Given a $13.00 Price Target by Maxim Group Analysts

Maxim Group set a $13.00 price objective on INmune Bio (NASDAQ:INMB) in a report published on Thursday morning, TipRanks reports. The brokerage currently has a buy rating on the stock.

NASDAQ:INMB opened at $10.82 on Thursday. INmune Bio has a fifty-two week low of $7.00 and a fifty-two week high of $11.50.

In other INmune Bio news, Chairman Raymond Joseph Tesi acquired 11,100 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were purchased at an average cost of $9.90 per share, with a total value of $109,890.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Linda F. Powers acquired 61,667 shares of the stock in a transaction that occurred on Wednesday, May 8th. The stock was acquired at an average cost of $9.00 per share, for a total transaction of $555,003.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 77,767 shares of company stock worth $709,893.

INmune Bio Company Profile

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

See Also: What are gap-up stocks?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.